Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups

Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups

Bibliographic Details
Main Authors: A’Hern Roger, DeBono Johann, Sandhu Shahneen, Kalaitzaki Eletheria, Usdin Martine, Hall Emma E
Format: Article
Language:English
Published: BMC 2011-12-01
Series:Trials
id doaj-c39da1cc779441ae8ec4eb9ba0a1e3d0
record_format Article
spelling doaj-c39da1cc779441ae8ec4eb9ba0a1e3d02020-11-25T02:34:00ZengBMCTrials1745-62152011-12-0112Suppl 1A8810.1186/1745-6215-12-S1-A88Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroupsA’Hern RogerDeBono JohannSandhu ShahneenKalaitzaki EletheriaUsdin MartineHall Emma E
collection DOAJ
language English
format Article
sources DOAJ
author A’Hern Roger
DeBono Johann
Sandhu Shahneen
Kalaitzaki Eletheria
Usdin Martine
Hall Emma E
spellingShingle A’Hern Roger
DeBono Johann
Sandhu Shahneen
Kalaitzaki Eletheria
Usdin Martine
Hall Emma E
Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups
Trials
author_facet A’Hern Roger
DeBono Johann
Sandhu Shahneen
Kalaitzaki Eletheria
Usdin Martine
Hall Emma E
author_sort A’Hern Roger
title Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups
title_short Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups
title_full Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups
title_fullStr Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups
title_full_unstemmed Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups
title_sort phase ii investigation of a parp inhibitor (olaparib) in castration resistant prostate cancer (crpc) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups
publisher BMC
series Trials
issn 1745-6215
publishDate 2011-12-01
work_keys_str_mv AT ahernroger phaseiiinvestigationofaparpinhibitorolaparibincastrationresistantprostatecancercrpcwhichincorporatesthepossibilitythattreatmenteffectmayberestrictedtobiomarkerdefinedsubgroups
AT debonojohann phaseiiinvestigationofaparpinhibitorolaparibincastrationresistantprostatecancercrpcwhichincorporatesthepossibilitythattreatmenteffectmayberestrictedtobiomarkerdefinedsubgroups
AT sandhushahneen phaseiiinvestigationofaparpinhibitorolaparibincastrationresistantprostatecancercrpcwhichincorporatesthepossibilitythattreatmenteffectmayberestrictedtobiomarkerdefinedsubgroups
AT kalaitzakieletheria phaseiiinvestigationofaparpinhibitorolaparibincastrationresistantprostatecancercrpcwhichincorporatesthepossibilitythattreatmenteffectmayberestrictedtobiomarkerdefinedsubgroups
AT usdinmartine phaseiiinvestigationofaparpinhibitorolaparibincastrationresistantprostatecancercrpcwhichincorporatesthepossibilitythattreatmenteffectmayberestrictedtobiomarkerdefinedsubgroups
AT hallemmae phaseiiinvestigationofaparpinhibitorolaparibincastrationresistantprostatecancercrpcwhichincorporatesthepossibilitythattreatmenteffectmayberestrictedtobiomarkerdefinedsubgroups
_version_ 1724810810494025728

Similar Items